REQUEST PRICE

Fields with * are required
Any questions? Contact us+49 761-389 49-0

Seraseq® Genomic DNA Tumor Mutational Burden (TMB) Mix Score 13

Seraseq® Genomic DNA Tumor Mutational Burden (TMB) Mix Score 13

Seraseq® Genomic DNA Tumor Mutational Burden (TMB) Mix Score 13

#0710-1586 Reference standards are made from human lung cancer cell lines and their matched “normal” cell lines from peripheral blood of the same patients.
€1,995.00 *

Prices plus VAT plus shipping costs

Delivery time 7 Workdays

Size: 2 x 500 ng
Preis anfragen

Fields with * are required
  • 0710-1586
In Immuno-Oncology, the goal is to enable a patient’s immune system to locate and eliminate... more
In Immuno-Oncology, the goal is to enable a patient’s immune system to locate and eliminate cancerous cells. The immune system may normally protect against cancer – except, when cancers manage to evade it – since immunocompromised individuals have a higher likelihood of developing cancer. Checkpoint inhibitors, which have recently improved the prognosis for a significant number of cancer patients, work by blocking inhibitory molecules such as PD-L1 and CTLA-4 that may be allowing cancers to evade the adaptive immune system. However, by taking the brakes off the immune system, the use of checkpoint inhibitors is associated with a significant risk of developing autoimmune disease. Additionally, frequently checkpoint inhibitors are not effective.In order to maximize the safety and efficacy of checkpoint inhibitors, it is beneficial to identify patients who are likely to respond to their use. Since the adaptive immune system can detect changes to proteins, it is thought that the number of somatic mutations that lead to such changes may be correlated with efficacy. The metric of non-silent somatic mutations per megabase of coding DNA has been termed Tumor Mutational Burden (TMB), which has shown some correlation to the efficacy of checkpoint inhibitors. Assessments of TMB are being added to many NGS assays to enable their use for patient selection in I-O clinical trials, and perhaps as companion diagnostics to these therapies. However, it is also known that TMB scores can differ significantly between assays and especially around levels that may be clinical decision points.

For additional information about the product, please visit the manufacturer's website.
PROPERTIES
storage temperature: -20°
shipping method: dry ice
regulatory status: RUO
Viewed